Biotech is Changing the Game


    Over the last 20 years the genetic makeup of life, as we understand it DNA, which has completed an amazing scientific cycle. Dating back to 1953 when it was a mysterious blur on an X-ray diffract ram. By the time 1970 came around, it was possible to identify the sequence of short nucleotide chains. Now a scientist can produce his or her own genetic code of choice with the click of a button.
    The result after the buttons clicked, after an order for a chain of DNA is sent, is an impressive series of events that supports one of the most mature and dynamic sectors of the biotech industry. DNA synthesis companies range from dull startups to Cambridge area giants, each using a specific set of tools that cuts out a piece of the ever increasing pie.
    Various industries are receiving the benefits from agriculture to clean-tech to pharmaceuticals. Emily Leproust, CEO of Twist Bioscience, thinks the biochemical arms race between pathogens and pharmaceutical companies is worse than what the majority people understand. With the rise in antibiotic resistance and a diminished rate of new antibiotic discovery, “we’re going back to an era of pre-penicillin,” Leproust stabilizes, “and it will be a shock to people.” With an affordable means to produce alternative genes, regulatory structures, or even entire metabolic pathways that are currently available, the depth of potential products has grown exponentially. “Now we can make new candidates and new antibiotics that will enable us to start fighting back.”


    Please enter your comment!
    Please enter your name here